On February 4, 2022, Nuvectis Pharma, Inc. (the "Company"), reported that entered into an Underwriting Agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein (the "Underwriters") (Filing, Nuvectis Pharma, FEB 4, 2022, View Source [SID1234607776]). Pursuant to the Underwriting Agreement, the Company agreed to sell in an underwritten offering (the "Offering") an aggregate of 3,200,000 shares (the "Shares") of the Company’s common stock, par value $0.00001 per share (the "Common Stock"), at an offering price of $5.00 per share, for gross proceeds of $16,000,000, less underwriting discounts and commissions and offering expenses. The Shares are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-260099), initially filed with the Securities and Exchange Commission (the "Commission") on October 6, 2021, as amended, and declared effective on February 4, 2022. The Company subsequently filed a registration statement on Form S-1MEF (File No. 333-262512) pursuant to Rule 462(b) under the Securities Act of 1933, as amended, which was effective immediately upon filing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The closing of the Offering is subject to satisfaction of customary closing conditions set forth in the Underwriting Agreement and is expected to occur on or about February 8, 2022.

The summary of the Underwriting Agreement set forth above does not purport to be complete and is subject to and qualified in its entirety by reference to the text of the Underwriting Agreement, a form of which is filed herewith as Exhibit 1.1. The Underwriting Agreement includes customary representations, warranties, closing conditions and covenants by the Company and the Underwriters.

On February 4, 2022 Nuvectis Pharma, Inc. (Nasdaq: NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology, reported the pricing of its initial public offering of 3,200,000 shares of common stock at a public offering price of $5.00 per share, for gross proceeds of $16,000,000, before deducting underwriting discounts and commissions and offering expenses (Press release, Nuvectis Pharma, FEB 4, 2022, View Source [SID1234607770]). In addition, the Company has granted the underwriter a 30-day option to purchase additional 480,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

The Company intends to use the proceeds to fund the Phase 1/2 development of NXP800, the IND-enabling studies of NXP900, to continue development and sponsored research related to its current product candidates or any future product candidate, hiring of additional personnel, capital expenditures, costs of operating as a public company, and other general corporate purposes.

Nuvectis’ shares of common stock are expected to begin trading on the Nasdaq Capital Market today under the symbol "NVCT." The offering is expected to close on or about February 8, 2022, subject to the satisfaction of customary closing conditions.

The shares of common stock described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-260099) previously filed with the Securities and Exchange Commission ("SEC") and became effective on February 4, 2022 and an additional registration statement on Form S-1 filed pursuant to Rule 462(b) which became automatically effective on February 4, 2022. This offering is being made only by means of a prospectus. Electronic copies of the final prospectus, when available, may be obtained by contacting H.C. Wainwright & Co., LLC, at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or by email at [email protected]. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at View Source

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On February 4, 2022 Prescient Therapeutics Limited (ASX: PTX) engaged in evolving personalized therapies for cancer reported for the December quarter of the current fiscal year (Press release, Prescient Therapeutics, FEB 4, 2022, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-asxptx-tables-impressive-results-for-december-quarter [SID1234607768]). The results reflect Prescient has anchored itself at a strong clinical and financial position in the industry. It worked its way through the quarter achieving crucial clinical and business development milestones.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The action-packed December quarter

During the quarter, Prescient made persistent progress in several anti-cancer therapy programs and projects aiming overall advancement in cancer treatment for patients worldwide.

The ASX-listed firm ended the quarter with a cash balance of AU$14.77 million. During the quarter, the firm received a tax refund of AU$1.33 million under Australian Government Research and Development.

Prescient presented new OmniCAR pre-clinical data at California’s Cell & Gene Meeting on the Mesa, one of the prominent platforms for international medical and investment community engaged in development of novel cell therapies. The new data included the prime features of OmniCAR to generate CAR-T cell therapies that can be controlled post-infusion; re-armed; and redirected from one cancer antigen to another. Also, significant dose-response cancer killing activity and high potency were demonstrated.

Physician-scientist Dr Marco Davila of the Moffitt Cancer Center and bioengineering expert Professor Andrew Tsourkas of the University of Pennsylvania joined firm’s multi-disciplinary expert international Scientific Advisory Board (SAB) in November 2021.

After the reporting period, Prescient has been successful in securing accreditation from the Office of the Gene Regulator (OTGR) for OmniCAR clinical studies. As per the Gene Technology Act 2000, the Instrument of Accreditation is a requisite for a firm in Australia to hold clinical trials that involve gene-edited cells, like CAR-T therapies.

The clinical-stage oncology company is looking forward to go beyond the ambit of growth and development and achieve bigger milestones in the coming quarters of the year. It will continue to work on its key clinical and pre-clinical trials to bring in relief for cancer patients.

The firm is dedicatedly working to evolve next-generation of targeted therapies that can help doctors in cancer treatment. New developments will also give way to long-term shareholder value.

On February 4, 2022 Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, reported that company management will participate in the following upcoming investor conferences (Press release, Asher Biotherapeutics, FEB 4, 2022, View Source [SID1234607762]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

4th Annual Guggenheim Oncology Conference
Craig Gibbs, Ph.D., will present a corporate overview on Friday, February 11, 2022 at 1:00 p.m. ET (10:00 a.m. PT). Company management will also participate in 1×1 meetings on Friday, February 11, 2022.

SVB Leerink 11th Annual Global Healthcare Conference
Company management will participate in 1×1 meetings on Monday, February 14 and Tuesday, February 15, 2022.

On February 4, 2022 FibroGen, Inc. (NASDAQ: FGEN) reported that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST (Press release, FibroGen, FEB 4, 2022, View Source [SID1234607761]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio webcast of the event will be available on the "Events & Presentations" section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days.